Pharming Group NV (PHARM) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.121x

Based on the latest financial reports, Pharming Group NV (PHARM) has a cash flow conversion efficiency ratio of 0.121x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€32.03 Million ≈ $37.44 Million USD) by net assets (€264.64 Million ≈ $309.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Pharming Group NV - Cash Flow Conversion Efficiency Trend (2005–2024)

This chart illustrates how Pharming Group NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Pharming Group NV for a breakdown of total debt and financial obligations.

Pharming Group NV Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Pharming Group NV ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Universal Insurance Holdings Inc NYSE:UVE	0.126x
Asiainfo Security Technologies Corp. A SHG:688225	N/A
Maccura Biotechnology Co Ltd SHE:300463	0.023x
Guoguang Electric Co Ltd SHE:002045	0.004x
Zhejiang Cayi Vacuum Container Co. Ltd. SHE:301004	0.126x
Guangzhou Metro Design And Research SHE:003013	0.032x
Matrix Design Co. Ltd. A SHE:301365	N/A
Lonkey Industrial Co Ltd Guangzhou SHE:000523	0.006x

Annual Cash Flow Conversion Efficiency for Pharming Group NV (2005–2024)

The table below shows the annual cash flow conversion efficiency of Pharming Group NV from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see PHARM market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€214.16 Million ≈ $250.38 Million	€-1.79 Million ≈ $-2.10 Million	-0.008x	+91.51%
2023-12-31	€198.05 Million ≈ $231.55 Million	€-19.55 Million ≈ $-22.85 Million	-0.099x	-188.20%
2022-12-31	€204.64 Million ≈ $239.24 Million	€22.90 Million ≈ $26.77 Million	0.112x	-40.31%
2021-12-31	€192.72 Million ≈ $225.31 Million	€36.13 Million ≈ $42.23 Million	0.187x	-62.14%
2020-12-31	€183.73 Million ≈ $214.80 Million	€90.98 Million ≈ $106.36 Million	0.495x	-22.12%
2019-12-31	€117.26 Million ≈ $137.09 Million	€74.56 Million ≈ $87.16 Million	0.636x	-2.76%
2018-12-31	€70.64 Million ≈ $82.58 Million	€46.19 Million ≈ $54.00 Million	0.654x	-67.83%
2017-12-31	€22.56 Million ≈ $26.37 Million	€45.84 Million ≈ $53.60 Million	2.032x	+658.01%
2016-12-31	€28.89 Million ≈ $33.77 Million	€-10.52 Million ≈ $-12.30 Million	-0.364x	+47.13%
2015-12-31	€26.06 Million ≈ $30.47 Million	€-17.95 Million ≈ $-20.99 Million	-0.689x	-289.43%
2014-12-31	€36.29 Million ≈ $42.43 Million	€-6.42 Million ≈ $-7.50 Million	-0.177x	+89.31%
2013-12-31	€6.92 Million ≈ $8.09 Million	€-11.45 Million ≈ $-13.39 Million	-1.655x	-223.33%
2012-12-31	€-10.12 Million ≈ $-11.83 Million	€-13.58 Million ≈ $-15.88 Million	1.342x	-89.84%
2011-12-31	€-1.54 Million ≈ $-1.80 Million	€-20.34 Million ≈ $-23.78 Million	13.210x	+2676.91%
2010-12-31	€13.43 Million ≈ $15.70 Million	€-6.89 Million ≈ $-8.05 Million	-0.513x	+64.11%
2009-12-31	€19.07 Million ≈ $22.30 Million	€-27.24 Million ≈ $-31.85 Million	-1.428x	-75.31%
2008-12-31	€17.45 Million ≈ $20.40 Million	€-14.21 Million ≈ $-16.62 Million	-0.815x	-30.04%
2007-12-31	€50.58 Million ≈ $59.13 Million	€-31.69 Million ≈ $-37.05 Million	-0.626x	-59.15%
2006-12-31	€65.78 Million ≈ $76.91 Million	€-25.89 Million ≈ $-30.27 Million	-0.394x	+12.20%
2005-12-31	€34.04 Million ≈ $39.79 Million	€-15.26 Million ≈ $-17.84 Million	-0.448x	--

About Pharming Group NV

AS:PHARM Netherlands Biotechnology

Market Cap

$1.17 Billion

€997.66 Million EUR

Market Cap Rank

#9427 Global

#55 in Netherlands

Share Price

€1.43

Change (1 day)

+1.38%

52-Week Range

€0.76 - €1.78

All Time High

€1.78